

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

ROXANE LABORATORIES, INC. and PAR PHARMACEUTICAL, INC.
Petitioners,

v.

JAZZ PHARMACEUTICALS, INC.
Patent Owner

Case CBM2014-00175
Patent 7,765,107

**PATENT OWNER PRELIMINARY RESPONSE
PURSUANT TO 35 U.S.C. § 323 and 37 C.F.R. § 42.207**

TABLE OF CONTENTS

	<u>Page</u>
I. INTRODUCTION	1
II. BACKGROUND	3
A. The Challenge of Restricting Access to a Dangerous But Efficacious Drug.....	4
B. The '107 Patent	7
III. ARGUMENT.....	8
A. The '107 Patent Does Not Claim A Method or Corresponding Apparatus for Performing Data Processing or Other Operations Used in the Practice, Administration, or Management of a Financial Product or Service	8
1. Covered Business Method Review Eligibility.....	9
2. The Statute Precludes Expansion of CBM Review to Encompass All Methods “Used In Commerce”	10
(a) Legislative History Does Not Support Petitioners’ Statutory Construction	12
(b) Petitioners’ “Used in Commerce” Argument Improperly Expands the Scope of CBM Review To Cover Virtually All Method Patent Claims.....	16
(c) Petitioners’ Argument Improperly Expands the Scope of CBM Review to Capture the Type of Invention Congress Expressly Stated Would Not Be CBM-Review Eligible	18
3. Petitioners Fail to Show that the Claims of the '107 Patent Cover a Financial Product or Service	19

- (a) The Claims of the '107 Patent Do Not Cover Activities Directly or Incidentally Related to a Financial Product or Service19
- (b) Petitioners Fundamentally Mischaracterize the Claims and Improperly Read In Limitations That Are Not Encompassed by the Claims21
- 4. Petitioners Fail to Show that Disclosures in the '107 Patent's Specification Relate to The CBM-Eligibility of the Claims28
- 5. Mere Classification Within Class 705 Does Not Make a Patent Eligible for CBM Review31
- 6. Prior Art Asserted Against the '107 Patent, with no Relation of the Portions of the Prior Art Cited to the Claims of the '107 Patent, Does Not Make the '107 Patent Eligible for CBM Review34
- B. The Claims of the '107 Patent Are Directed To A Technological Invention.....36
 - 1. The '107 Patent Recites a Technological Feature that is Novel and Unobvious Over the Prior Art36
 - 2. The '107 Patent's Claims Solve a Technical Problem Using a Technical Solution.....42
- C. Petitioners Fail to Prove that the ACA is Prior Art.....45
 - 1. Petitioners' Wayback Machine Evidence Does Not Establish A Publication Date Prior to the '107 Patent's Priority Date47
 - 2. Petitioners' Other Materials Do Not Establish Public Accessibility53
- IV. CONCLUSION.....56

I. INTRODUCTION

Pursuant to 35 U.S.C. § 323 and 37 C.F.R. § 42.207(a), Patent Owner Jazz Pharmaceuticals, Inc. (“Jazz”) submits this Preliminary Response to Roxane Laboratories, Inc. and Par Pharmaceutical, Inc.’s (“Petitioners”) Petition for Covered Business Method (“CBM”) review (the “Petition”) of U.S. Patent No. 7,765,107 (the “’107 patent”). For the reasons discussed below, the Petitioners fail to meet the threshold requirement to show that the ’107 patent is a covered business method patent under the statute and subject to CBM review. The Patent Trial and Appeal Board (the “Board”), therefore, should not institute review of the ’107 patent. Petitioners also fail to show that the Advisory Committee Art (“ACA”) materials constitute prior art to the ’107 patent. Accordingly, even if the Board does not deny the Petition in its entirety, it should not institute Petitioners’ second (§ 102(b)) and third (§ 103(a)) grounds for unpatentability.

The claims of the ’107 patent cover methods of controlling the abuse, misuse and diversion of a prescription drug, particularly a drug containing GHB—a substance notorious for its illicit use in drug-facilitated sexual assaults. The claims specifically cover the methods ultimately approved by FDA to ensure the safe administration of Jazz’s FDA-approved form of sodium GHB—Xyrem[®]—to treat patients while preventing the abuse, misuse, and diversion known to have occurred with illicit forms of this drug. Xyrem is the *only* approved treatment for cataplexy,

a debilitating symptom of narcolepsy, and excessive daytime sleepiness in patients with narcolepsy. The technological solution to the problem of how to get Xyrem to patients who need it, while mitigating the risk of abuse, misuse or diversion of this drug, was critical to Xyrem's approval by the FDA. The solution resulted in the claimed methods which utilize a computer processor/central database controlled only by an exclusive entity, which have numerous safety checks and/or controls, including restriction of availability, extensive determination of patient and physician identity, and identification of behavioral patterns that suggest illicit drug use.

By statute, a patent is subject to CBM review only if the patent "claims a method or corresponding apparatus for performing data processing or other operations used in the practice, administration, or management of a *financial product or service*. . . ." AIA § 18(d)(1); 37 C.F.R. 42.301(a) (emphasis added). Petitioners cannot meet their burden to establish that the '107 patent covers "data processing or other operations used in the practice, administration, or management of a financial product or service" because the '107 patent has nothing to do with a financial product or service. Here, the '107 patent's claims do not cover a financial product or service, or any activities incidental to a financial product or service. As a result of Petitioners' improper attempt to expand the scope of CBM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.